

Neuromuscular aspects of Duchenne Muscular Dystrophy

Parent JOIN THE FIGHT.
END DUCHENNE.
Project
Muscular
Dystrophy

Jena Krueger
August 21, 2022

Conflict of interest

I am currently or was previously a principal investigator for funded pharmaceutical trials with Avexis/Novartis*, Scholar Rock Inc, Fibrogen and Genentech

* Published work at least partially produced utilizing medical writers supported by pharmaceutical company

This presentation may include non-FDA approved use of medication and treatment in pediatric neuromuscular disorders



#PPMDConference


Objectives

- Define Duchenne Muscular Dystrophy
- Discuss the multidisciplinary care model



History¹

- Described by Meryon, 1852 and Little in 1853
- 1861 Duchenne established diagnostic criteria
- Becker Muscular Dystrophy described in 1955
- DMD gene mapped on Xp21




Duchenne Muscular Dystrophy

- Absent or deficient dystrophin
- Dystrophin = protein responsible for strength, stability, function of muscle fibers²




DMD gene³



#PPMDCConference


Genetics

Chromosome to Gene to Protein



Genetics

Types of Gene Mutations



Missense Mutations change one word or letter

THE CAR WAS RED. → THE CAR WAS HAI.
→ THE CAR WAS RDD.

Insertion Mutations add one word or letter

THE CAR WAS RED. → THE CAR WAS RED RED.
→ THE CAR WAS ERED.


Nonsense Mutations end the instructions too soon

THE CAR WAS RED. → THE CAR. _____

Deletion Mutations change the meaning by subtracting words or letters

THE CAR WAS RED. → THE WAS RED.
→ THE _AR WAS RED.

DMD Care⁴



#PPMDConference

Multidisciplinary Clinic Visit

- Height/Weight
- Neurology
- Pulmonary
- Physical Therapy
- Social Work
- Genetics
- Treatment
- Cardiology
EKG, ECHO/cMRI
- Endocrine
DEXA / X-Ray
- Orthopedics
- Rehabilitation
- Durable
Medical
Company
- Orthotics
- Speech therapy
- Occupational
Therapy
- Neuropsych
- Palliative Care





Google images



#PPMDConference

Neurology's Role²

- Evaluate each patient individually
- Establish baseline and trajectory with validated assessment tools
- Management
 - Medications, research options
 - Respiratory and cardiac technology
 - Surgical options: scoliosis, contractures
- Coordinate multidisciplinary team



Treatment²

- Steroids
- Approved therapies
 - Exon skipping
- Treating symptoms (constipation, sleep, ect)
- Research options
- PT and Stretching
- Orthotics




Steroids

- Prednisone
- Deflazacort (Emflaza)



#PPMDConference



Steroids

- Able to walk longer
- Arms stay stronger longer
- Helps to keep breathing muscles strong
- Avoid scoliosis surgery
- Delays cardiomyopathy (heart dysfunction)
- Improves survival

- BUT ... steroids have side effects too



Prednisone

Preferred by US insurance
More behavioral side effects
More like to cause diabetes
More weight gain

Deflazacort

More like to cause cataracts
Decreased height
More osteopenia

Both improve strength (compared to placebo)

*deflazacort may be more effective at delaying loss of muscle strength, motor function

Daily and weekend only regimens were both effective



Monitoring

- Height, Weight, BP
- QOL
- New symptoms or concerns
- Labs
- Pulmonary function testing
- EKG / ECHO



Monitoring

- PT assessment every 6 months
 - Range of motion, strength
 - North Star Ambulatory Assessment, timed function tests (6MWT)
 - BayleyIII and Griffiths mental development in infants
 - Brooke upper extremity, Egan Klassifikation in non-ambulatory



After your appointment

- Daily Stretching !! 4-6 times per week
- AFO
 - Night while ambulatory, day if non-ambulatory
- Submaximal, aerobic exercise (swimming, cycling)
 - Avoid high-resistance, over exertion



References

1. BT Darras, CC Menache-Starobinski, V Hinton, L Kunkel. “Dystrophinopathies” ch 30, p551-592. BT Darras, H Royden Jones Jr., MM Ryan and DC De De Vivo (Eds): Neuromuscular disorders of Infancy, Childhood and Adolescence, 2nd ed.
2. DJ Birnkrant, K Bushby, CM Bann, et al “Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine and gastrointestinal and nutritional management” Lancet Neurology 2018
3. www.parentprojectmd.org
4. DJ Birnkrant, K Bushby, CM Bann, et al “Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, orthopedic management” Lancet Neurology 2018
5. DJ Birnkrant, K Bushby, CM Bann, et al “Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care and transitions of care across the lifespan” Lancet Neurology 2018
6. WD Biggar, A Skalsky, CM McDonald “Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy”. Journal of Neuromuscular Diseases 9 (2022) 463-476



Thank you!